Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Imatinib-induced dose-dependent interstitial lung disease successfully switched to nilotinib: a case report with concentration exposure data.

Literature DB >> 23271413

Imatinib-induced dose-dependent interstitial lung disease successfully switched to nilotinib: a case report with concentration exposure data.

Kim Dao, Dana Védy, José Lopez, Olivier Staneczek, Thierry Buclin, Françoise Livio.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2012 PMID： 23271413 DOI： 10.1007/s12185-012-1250-3

Source DB: PubMed Journal: Int J Hematol ISSN： 0925-5710 Impact factor: 2.490

× No keyword cloud information.

10 in total

1. Hypersensitivity pneumonitis related to imatinib mesylate.

Authors: A Bergeron; E Bergot; G Vilela; L Ades; A Devergie; H Espérou; G Socié; F Calvo; E Gluckman; P Ribaud; Ph Rousselot; A Tazi
Journal: J Clin Oncol Date: 2002-10-15 Impact factor: 44.544

Review 2. Joining the DoTS: new approach to classifying adverse drug reactions.

Authors: J K Aronson; R E Ferner
Journal: BMJ Date: 2003-11-22

3. Corticosteroid-responsive interstitial pneumonitis related to imantinib mesylate with successful rechallenge, and potential causative mechanisms.

Authors: P Grimison; D Goldstein; J Schneeweiss; N Murray
Journal: Intern Med J Date: 2005-02 Impact factor: 2.048

4. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate.

Authors: K Ohnishi; F Sakai; S Kudoh; R Ohno
Journal: Leukemia Date: 2006-06 Impact factor: 11.528

Review 5. Treatment options for chronic myeloid leukemia.

Authors: Maria Florencia Tanaka; Hagop Kantarjian; Jorge Cortes; Maro Ohanian; Elias Jabbour
Journal: Expert Opin Pharmacother Date: 2012-03-19 Impact factor: 3.889

6. Lack of recurrence of imatinib-induced interstitial lung disease with nilotinib.

Authors: Thomas Delomas; Christian Darné; Caroline Besson
Journal: Leuk Lymphoma Date: 2011-09-19

7. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series.

Authors: Anne Bergeron; Delphine Réa; Vincent Levy; Clément Picard; Véronique Meignin; Jérome Tamburini; Heriberto Bruzzoni-Giovanelli; Fabien Calvo; Abdellatif Tazi; Philippe Rousselot
Journal: Am J Respir Crit Care Med Date: 2007-06-28 Impact factor: 21.405

8. Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib.

Authors: Paul W Manley; Nikolaus Stiefl; Sandra W Cowan-Jacob; Susan Kaufman; Jürgen Mestan; Markus Wartmann; Marion Wiesmann; Richard Woodman; Neil Gallagher
Journal: Bioorg Med Chem Date: 2010-08-14 Impact factor: 3.641

Review 9. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib.

Authors: Oliver Hantschel; Uwe Rix; Giulio Superti-Furga
Journal: Leuk Lymphoma Date: 2008-04

10. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib.

Authors: Elizabeth Day; Beatrice Waters; Katrin Spiegel; Tanja Alnadaf; Paul W Manley; Elisabeth Buchdunger; Christoph Walker; Gabor Jarai
Journal: Eur J Pharmacol Date: 2008-10-11 Impact factor: 4.432

10 in total

5 in total

Review 1. Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas.

Authors: Rashmi R Shah
Journal: Drug Saf Date: 2016-11 Impact factor: 5.606

2. Imatinib-Induced Interstitial Pneumonitis Successfully Switched to Nilotinib in a Patient with Prior History of Mycobacterium tuberculosis Infection.

Authors: Zhuan Bo Luo; Ning Xu; Xiao Ping Huang; Gui Fang Ouyang
Journal: Turk J Haematol Date: 2017-07-28 Impact factor: 1.831